Opioid Induced Constipation Market Share, Size, Trends, Industry Analysis Report, By Active Ingredients; By Prescription Type; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032
- Published Date:Jan-2024
- Pages: 116
- Format: PDF
- Report ID: PM4344
- Base Year: 2023
- Historical Data: 2019 – 2022
Report Outlook
Opioid Induced Constipation Market size was valued at USD 2.63 billion in 2023. The market is anticipated to grow from USD 2.74 billion in 2024 to USD 3.93 billion by 2032, exhibiting a CAGR of 4.6% during the forecast period.
Market Overview
Opioid-induced constipation often occurs among the population when they consume opioids, which are mostly consumed to get relief from pain. As of November 2021, data from the Centers for Disease Control and Prevention indicate a rise in the number of opioid prescriptions, with an increase of 153,260,450 in 2019 and 142,816,781 in 2020. One of the major causes of constipation with opioid intake is that it lowers the normal function of the digestive system and forces the stool to dry and become hard. It causes staining to the anus muscles, making it hard to relax, necessitating the need for opioid-induced constipation treatment in the marketplace. The ongoing research studies are enhancing the opioid-induced market size in the global market.
- For instance, in November 2023, a study published in the Journal of Pain Research focused on testing the ability of methylnaltrexone in treating opioid-induced constipation among critically ill patients and found it was superior in attaining rescue-free laxation in them.
Enhanced healthcare infrastructure, a surge in chronic pain cases among adults, and growing unmet healthcare needs have led to an increased demand for innovative drugs, particularly for addressing opioid borne constipation. The growth these drugs is anticipated to be driven by emerging countries. Moreover, there is a substantial demand for increased government investments to improve healthcare infrastructure, deliver enhanced healthcare services, and foster medical tourism in these developing nations, thereby contributing significantly to the expansion of the healthcare sector in these economies.
To Understand More About this Research: Request a Free Sample Report
Moreover, apart from the ability of opioids to enhance the quality of life by lessening pain, 18.9% of the patients are showing interest in stopping their use due to their side effects. The significant benefits of opioids, along with their side effects, are driving the potential demand for opioid-induced constipation.
Growth Drivers
The presence of an elderly population
One of the main factors contributing to the increased demand for opioids is the growing elderly population at the global level. As the elderly population becomes more vulnerable to arthritis, cancer, back pain, and more, there will be a significant rise in the need for painkillers, including opioid-related drugs, facilitating the opportunities for the opioid-induced constipation market in the next few years.
As per the World Health Organization Facts 2021, it is projected that by 2030, one out of every six individuals globally will be 60 years old or older. The population of individuals aged 60 and above is anticipated to increase from 1 billion in 2020 to 1.4 billion by 2050. Furthermore, the global population of individuals aged 60 and above is expected to double by 2050, reaching 2.1 billion. Notably, between 2020 and 2050, the number of individuals aged 80 and above is predicted to triple, reaching 426 million.
The significant rise in opioid prescriptions
The increasing demand for opioids is expected to contribute to the demand for opioid-induced constipation in the market. For instance, in December 2022, the opioid prescription from surgeons contained around 44 pills, which is normally higher than the patients required after surgery. This trend is expected to positively influence the demand for opioid-induced constipation during the study period.
Restraining Factors
The declining use of opioids in the marketplace
Healthcare providers as well as patients are gaining information about numerous therapies and medicines with the increased accessibility of the internet. This is reducing the asymmetry of information about the pharmaceutical products on the market and enabling them to know the side-effects associated with them before use. This is likely to hamper the requirement for opioid-induced constipation in the market.
Report Segmentation
The market is primarily segmented based on active ingredients, prescription type, route of administration, distribution channel and region.
|
By Active Ingredients |
By Prescription Type |
By Route of Administration |
By Distribution Channel |
By Region |
|
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
By Active Ingredients Analysis
Naloxegol segment is expected to witness the highest growth during the forecast period
The naloxegol segment is projected to grow at a CAGR during the projected period, mainly driven by its safety profile and effectiveness in treating opioid-induced constipation. A 2021 study focused on testing the potential capabilities of naloxegol among patients suffering from opioid-induced constipation. The result showcased its enormous strength in giving treatment to cancer pain patients.
By Treatment Analysis
Prescription segment registered for the largest market share in 2023
The prescription segment accounted for the largest share in 2023. The limited knowledge about the medicines needed for opioid-induced constipation among the population is likely to drive the necessity of consulting a doctor and taking a prescription around the world.
However, the rising number of internet users is likely to promote the utilisation of over-the-counter products in the marketplace, driving their significant adoption in the opioid-induced constipation market in the future.
By Distribution Channel Analysis
Retail pharmacy segment is anticipated to witness significant growth
The retail pharmacy segment is expected to register significant growth in the coming years, which is highly attributable to rising preferences for self-medication. The lower awareness and surrounding stigma associated with opioid-induced constipation are driving significant opportunities for retail pharmacies.
Regional Insights
North America region registered the largest share of the global market in 2023
The North America dominated the global market. This dominance is attributed to the rising use of painkillers. According to the U.S. Pain Foundation, over 20% of American adults experience chronic pain, and they are most likely to take prescribed pain relief drugs, including opioids, to cope with their pain. The cause of constipation is often one of the side effects of opioid-related painkillers. This trend is the major contributing factor in registering a larger opioid-induced constipation market share.
Asia Pacific will grow at the fastest pace, owing to the presence of a larger population base and the higher rate of senior citizens in the region. As these people adopt opioid-related painkillers due to their higher efficiency in granting relief from pain, there will be a significant demand in the future.
Key Market Players & Competitive Insights
Strategic collaborations to fuel the competition
The opioid-induced constipation market is moderately fragmented, with the presence of several players. The increased collaborative initiatives are likely to promote competition in the market. For instance, in August 2023, Kyowa Kirin Co. and Grünenthal GmbH entered a collaboration to establish a new venture to offer a combined portfolio of therapeutics, including Moventig, for opioid-induced constipation.
Some of the major players operating in the global market include:
- Abbott (US)
- Aurobindo Pharma (India)
- Bayer AG (Germany)
- Boehringer Ingelheim International GmbH. (Germany)
- Bristol Myers Squibb Company (US)
- Cosmo Pharmaceuticals (Ireland)
- Daewoong Pharmaceutical Company (South Korea)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Fresenius Kabi AG (Germany)
- GSK Plc. (UK)
- Hikma Pharmaceuticals PLC (UK)
- Merck & Co Inc. (US)
- Mylan NV (US)
- Novartis AG (Switzerland)
- Pfizer Inc (US)
Recent Developments in the Industry
- In November 2023, a study published in MDPI explored the use of opioid antagonists in line with dysbiosis and opioid-induced constipation in the present and future.
- In May 2022, a study published in Medical Science explored the effectiveness of itopride in the management of opioid-induced constipation among palliative care patients.
Report Coverage
The opioid induced constipation market report emphasizes on key regions across the globe to provide better understanding of the product to the users. Also, the report provides market insights into recent developments, trends and analyzes the technologies that are gaining traction around the globe. Furthermore, the report covers in-depth qualitative analysis pertaining to various paradigm shifts associated with the transformation of these solutions.
The report provides detailed analysis of the market while focusing on various key aspects such as competitive analysis, active ingredients, treatment, route of administration, end-users, distribution channel, and their futuristic growth opportunities.
Opioid Induced Constipation Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 2.74 billion |
|
Revenue forecast in 2032 |
USD 3.93 billion |
|
CAGR |
4.6% from 2024 – 2032 |
|
Base year |
2023 |
|
Historical data |
2019 – 2022 |
|
Forecast period |
2024 – 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Segments covered |
|
|
Regional scope |
|
|
Competitive Landscape |
|
|
Report Format |
|
|
Customization |
Report customization as per your requirements with respect to countries, region and segmentation. |
Gain profound insights into the 2024 Induced Opioid Induced Constipation Market with meticulously compiled statistics on market share, size, and revenue growth rate by Polaris Market Research Industry Reports. This thorough analysis not only provides a glimpse into historical trends but also unfolds a roadmap with a market forecast extending to 2032. Immerse yourself in the comprehensive nature of this industry analysis through a complimentary PDF download of the sample report.
Browse Our Top Selling Reports
UV Nail Gel Market Size, Share 2024 Research Report
Radiation Dose Management Market Size, Share 2024 Research Report
Automotive Brake System Market Size, Share 2024 Research Report
Inhalation Anesthesia Market Size, Share 2024 Research Report
Sugar Substitutes Market Size, Share 2024 Research Report
FAQ's
key companies in Opioid Induced Constipation Market are Abbott, Aurobindo Pharma, Bayer, Boehringer Ingelheim International
Opioid Induced Constipation Market exhibiting the CAGR of 4.6% during the forecast period.
The Opioid Induced Constipation Market report covering key segments are active ingredients, prescription type, route of administration, distribution channel and region.
key driving factors in Opioid Induced Constipation Market are presence of an elderly population
The global opioid induced constipation market size is expected to reach USD 3.93 billion by 2032
